J&J Medical Connect
ICOTYDE™

(icotrokinra)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

ICOTYDE™ (icotrokinra)

Medical Information

ICOTYDE - Use in Combination with Biologics in Patients with Plaque Psoriasis

Last Updated: 03/18/2026

SUMMARY

  • The company cannot recommend any practices, procedures or usage that deviate from the approved labeling.
  • ICOTYDE in combination with biologics has not been studied in patients with plaque psoriasis.
  • Exclusion criteria related to concomitant therapy in the ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE-2 phase 3 trials is listed below.1-3 

CLINICAL TRIAL PROTOCOLS

Exclusion Criteria

Prior or Concomitant Therapy

  • Previously received ICOTYDE.
  • Previously received deucravacitinib.1-3 
  • Experienced primary efficacy failure (no response within 16 weeks) to 1 or more agents directly targeting interleukin (IL)-23 or has had a clinically significant adverse event to 1 or more agents directly targeting IL-23.1-3 
  • Prohibited medications or class of medications are provided in Table: Select Prohibited Medications in Phase 3 Clinical Trials.

Select Prohibited Medications in Phase 3 Clinical Trials1-3 
Prohibited Medication or Class of Medications
Restriction Duration
Any biologic therapy, including but not limited to:
12 weeks or 5 half-lives, whichever was longer, prior to the first administration of study intervention
(through end of study)
   IL-23 inhibitors: guselkumab, tildrakizumab,
   risankizumab
   IL-17 inhibitors: secukinumab, brodalumab,
   ixekizumab
   IL-12/23 inhibitors: ustekinumab, briakinumab
   TNF-α antagonists: adalimumab, infliximab,
    etanercept, certolizumab, golimumab
   Natalizumab
   Belimumab
   Abatacept
   Visilizumab
   Experimental or investigational therapy
Abbreviations: IL, interleukin; TNF, tumor necrosis factor.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 04 February 2026.

References

Show
1 Bissonnette R, Soung J, Hebert AA, et al. Protocol to: Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784-1795.  
2 Gooderham M, Lain E, Bissonnette R, et al. Protocol to: Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12).  
3 Gold LS, Armstrong AW, Bissonnette R, et al. Supplement to: Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363-1374.